Elizabeth Cull, MD
Hematology & Oncology · Greenville, SCNPI 1356674527
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,631 of the $15,837 with a category attached, or 67.1%. Bristol Myers Squibb accounts for 87.6% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $8,384 and has fallen 92.7% since, to $609 in 2025.
Across 84 payments — averaging $188.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$14K
- AstraZeneca$344
- Pfizer$275
- Novartis$240
- AbbVie$141
- Amgen$109
- plus $852 from 29 others
Across 152 payments — averaging $7843.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aptevo Therapeutics Inc$265K
- Genentech, Inc.$238K
- Seagen Inc.$197K
- Merck$122K
- E.r. Squibb & Sons, L.L.C.$109K
- Bristol Myers Squibb$78K
- plus $183K from 8 others
What the payments were for
- Consulting fees$1,69511%
- Speaking & faculty fees$10,63167%
- Travel & lodging$1,2958%
- Food & beverage$2,09913%
- Education$1171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 15 | $13,875 |
| AstraZeneca(2 entities) | 6 | $344 |
| Pfizer | 4 | $275 |
| Novartis | 10 | $240 |
| AbbVie | 5 | $141 |
| Amgen | 1 | $109 |
| Johnson & Johnson | 3 | $68 |
| Genentech USA, Inc. | 3 | $52 |
| GSK | 2 | $50 |
| Merck | 2 | $48 |
| Stemline Therapeutics Inc. | 2 | $46 |
| Beone Medicines USA, Inc. | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Blueprint Medicines Corporation | 1 | $38 |
| Syndax Pharmaceuticals, Inc. | 2 | $35 |
| Rigel Pharmaceuticals, Inc. | 2 | $35 |
| Beigene USA, Inc. | 2 | $34 |
| Exelixis Inc. | 2 | $27 |
| Karyopharm Therapeutics Inc. | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Caris MPI, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Geron Corporation | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $17 |
| Seagen Inc. | 1 | $16 |
| Fennec Pharmaceuticals, Inc. | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,837 in reported general payments places this provider in the 80th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 119 | $1,967,790 |
| Lenalidomide | 56 | $800,887 |
| BrukinsaZanubrutinib | 57 | $727,276 |
| TasignaNilotinib Hcl | 52 | $702,057 |
| CalquenceAcalabrutinib Maleate | 40 | $603,409 |
| JakafiRuxolitinib Phosphate | 32 | $524,680 |
| PomalystPomalidomide | 24 | $467,420 |
| ImbruvicaIbrutinib | 21 | $299,753 |
| InqoviDecitabine/Cedazuridine | 32 | $261,014 |
| VenclextaVenetoclax | 48 | $202,343 |
| BosulifBosutinib | 11 | $155,620 |
| Posaconazole | 46 | $80,412 |
| PegasysPeginterferon Alfa-2a | 12 | $52,375 |
| EliquisApixaban | 41 | $25,676 |
| Atovaquone | 26 | $16,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $13,875 | $1,967,790119 claims |
| Beigene USA, Inc.Brukinsa | $34 | $727,27657 claims |
| NovartisTasigna | $240 | $702,05752 claims |
| AstraZenecaCalquence | $344 | $603,40940 claims |
| Incyte CorporationJakafi | $15 | $524,68032 claims |
| AbbVieVenclexta | $141 | $202,34348 claims |
| PfizerBosulif, Eliquis | $275 | $181,29652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Bhumika PatelGreenville$225K
- Joe StephensonGreenville$57K
- Kevin KoehlerGreenville$10K
- Paige GanemGreenville$9K
- Vikas DemblaSpartanburg$568K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Ming LimCharleston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.